hemodialysis

  1. T

    Graft Patency For Hemodialysis - Fish Oil Supplements Show Mixed Results

    A study in the May 2 issue of JAMA reveals that daily ingestion of fish oil did not lower the percentage of grafts with loss of patency, i.e. that remained open in patients with new synthetic arteriovenous grafts within 12 months. An arteriovenous graft is a synthetic tube that is grafted...
  2. T

    Affymax And Takeda Report Phase 2 Analyses Of Hematide™/peginesatide In Hemodialysis

    Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...
  3. T

    Affymax And Takeda Report Phase 2 Analyses Of Hematide™/peginesatide In Hemodialysis

    Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...
  4. T

    Affymax And Takeda Report Phase 2 Analyses Of Hematide™/peginesatide In Hemodialysis

    Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...
Back
Top